Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NCK1 | P16333 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541719 | 0.74 | CYP1A2 (0.38) | CYP1A2CYP2A6TDP1NCK1BACE1 | |
| SCHEMBL31216375 | 0.74 | CYP1A2 (0.38) | CYP1A2CYP2A6TDP1NCK1BACE1 | |
| SCHEMBL2616769 | 0.66 | CYP1A2 (0.60) | CYP1A2CYP2A6TDP1NCK1BACE1 | |
| SCHEMBL8350086 | 0.64 | CYP2A6 (0.44) | CYP1A2CYP2A6TDP1NCK1BACE1 | |
| SCHEMBL9724136 | 0.63 | CYP2A6 (0.48) | CYP1A2CYP2A6TDP1NCK1BACE1 | |
| SCHEMBL14344241 | 0.62 | KMT2A (0.46) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| SCHEMBL3282710 | 0.62 | KMT2A (0.37) | CYP1A2ALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL5460331 | 0.61 | ALDH1A1 (0.37) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| SCHEMBL5451536 | 0.61 | KDM4E (0.38) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| SCHEMBL12355607 | 0.60 | CYP1A2 (0.30) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619179-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038944-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | CYP1A2 2322/4885CYP2A6 1699/4885TDP1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.